Hosted on MSN17d
Blessing Health introduces new FDA-approved nasal spray treatment for resistant depression
The treatment is a nasal spray form of Ketamine recently approved by the FDA known as Esketamine ... show an average timeframe of 4 hours to 28 days for symptom improvement with Spravato ...
Business Insider6y
Regulators just approved the first new depression drug since the 1980s, and some see blockbuster potential
Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson, the drug is a nasal spray designed to treat severe forms of depression that don't respond to other medications.
Medpage Today on MSN2mon
FDA Expands Approval of Esketamine for Depression
The FDA approved esketamine (Spravato) nasal spray as monotherapy ... total score compared with placebo by day 28, with least ...
pharmaphorum3d
FDA approves Janssen’s ketamine-based nasal antidepressant
The FDA has approved Janssen’s antidepressant nasal spray Spravato ... through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen ...
Medindia6y
Esketamine Nasal Spray Can Prevent Suicidal Thoughts in Depression
Esketamine (a derivative of ketamine) nasal spray formulations can act fast and help reduce dangerous symptoms of major depression and suicidal thoughts found a new study. The findings of this ...
Mena FN11d
Esketamine Market Size, Growth Drivers And Global Forecast 2032 At A Thriving CAGR Of 7.90%
Esketamine, a nasal spray formulation of the S-enantiomer of ketamine, offers a novel mechanism of action, providing rapid relief for patients who have not responded to traditional antidepressants.